BioSpace News Archive

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief

Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets

Prespecified Analysis of 3,146 Patients in the USA Enrolled in REDUCE-IT Showed 31% Relative Risk Reductions for First Occurrence of Both 5-Point MACE and 3-Point MACE

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Interventional product portfolio including the MANTA® Vascular Closure Device and Langston® Dual Lumen Catheters at the PCR London Valves being held in London, United Kingdom on November, 17th – 19th, 2019.

Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2019.

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vice President of Discovery Research, Martin Handfield, MS, Ph.D., will be a featured speaker at the inaugural International Conference on Microbial Research and Applications (MicroBiome 2019).

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), announces that it will issue 80,645 common shares pursuant to a previously announced consulting agreement with Shaanxi Jintai Mining Co., Ltd to support Avivagen’s continued efforts in China.

Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), highlighted promising preclinical performance of the company’s thyroid hormone receptor beta (THR-β) agonist for NASH today at The Liver Meeting

NuProbe Global announced the launch of the VarTrace™ product line of Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies (VAF) down to 0.1%.

USA News Group – As the global oncology drug market is projected to grow at a rate of 7.6% CAGR to hit $176.5 billion by 2025, there’s a growing interest within the big pharma sector to tap into the power of viruses to fight cancer.